✦ LIBER ✦

Solar urticaria treated with intravenous immunoglobulins

✍ Scribed by Henri Adamski; Christophe Bedane; Annie Bonnevalle; Pierre Thomas; Jean-Louis Peyron; Bernard Rouchouse; Frederic Cambazard; Michel Jeanmougin; Manuelle Viguier

Book ID: 116586932
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 270 KB
Volume: 65
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2010.05.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Severe and refractory solar urticaria tr

Severe and refractory solar urticaria treated with intravenous immunoglobulins: A phase II multicenter study

✍ Aubin, François; Porcher, Raphaël; Jeanmougin, Michel; Léonard, Fabienne; Bedane 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Solar urticaria successfully treated wit

Solar urticaria successfully treated with intravenous immunoglobulin

✍ R. Hughes; C. Cusack; G. M. Murphy; B. Kirby 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Solar urticaria successfully treated wit

Solar urticaria successfully treated with intravenous immunoglobulin

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Solar urticaria treated successfully wit

Solar urticaria treated successfully with intravenous high-dose immunoglobulin: a case report

✍ Isabel Correia; João Silva; Paulo Filipe; Manuel Gomes 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

Solar urticaria unresponsive to intraven

Solar urticaria unresponsive to intravenous immunoglobulins

✍ Mar Llamas-Velasco; Diego De Argila; Cristina Eguren; Patricia García-Martin; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB

Intravenous immunoglobulin in autoimmune

Intravenous immunoglobulin in autoimmune chronic urticaria

✍ O'donnell; Barr; Kobza Black; Francis; Kermani; Niimi; Barlow; Winkelmann; Greav 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 476 KB

Histamine releasing autoantibodies play a central role in the pathogenesis of chronic urticaria (CU) in approximately 30% of affected patients. We investigated the therapeutic effect of high-dose intravenous immunoglobulin (IVIG) on disease activity in patients with severe CU of autoimmune aetiology